ArticleScientific reports2026
Mpox in people living with and without HIV, including people on PrEP, during a multistate outbreak in Spain in 2022.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Spain reported the highest cumulative incidence of mpox in Europe during the 2022 outbreak, which disproportionately affected people living with HIV (PLWH) and HIV-negative individuals using pre-exposure prophylaxis (PrEP). We conducted a multicentre cross-sectional study to analyze epidemiological, clinical, and disease progression characteristics of mpox among PLWH, HIV-negative individuals, and PrEP user cases and non-user cases in Spain. Data were collected from June 2022 to January 2023, including 1,158 men aged ≥ 18 years; 35.3% were PLWH and 42.7% of HIV-negative individuals were PrEP users. Adjusted OR and the 95% CI were calculated by multivariate logistic regression analysis. More frequently PLWH than HIV-negative cases were having sex only with men (aOR = 10.92;3.76–31.69), chemsex (aOR = 2.02;1.38–2.97), another type of immunosuppression (aOR = 2.57;1.07–6.21) and non-anogenital and non-oral exanthems (aOR = 1.64;1.23–2.19). More frequent in PLWH compared to PrEP user cases were lower education levels (aOR = 23.21;2.87–187.52), fever (aOR = 1.42;0.98–2.06), non-anogenital and non-oral exanthems (aOR = 2.40;1.67–3.45) and another type of immunosuppression (aOR = 9.32;1.16–75.16) and more frequent in PrEP user cases than in non-PrEP user cases were risk factors related to sexual activity and concurrent sexually transmitted infections. PLWH did not experience more severe mpox than HIV-negative persons. These findings underscore the need for tailored prevention and clinical approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.